The recent first global approval[1]  of dupilumab in the US has been reviewed in detail in the First Global Approval report in Adis’ journal Drugs[2], based on the development milestones tracked in AdisInsight.[3]

In September 2017 dupilumab (Dupixant®), developed by Sanofi and Regeneron, was also approved in the EU for use alone or in combination with corticosteroids in adult patients with moderate-to-severe atopic dermatitis who are candidates for systemic therapy.[4]

“People with moderate-to-severe atopic dermatitis can experience unbearable symptoms that may significantly impact their quality of life. Many often struggle to control their disease with the treatment options currently available,” said Christine Janus, Chief Executive Officer of the International Alliance of Dermatology Patient Organizations. “We support timely access to this important new medication for those with moderate-to-severe atopic dermatitis to help them control and provide relief for this life-altering, often severely debilitating, chronic disease.” [4]

For further information related to the first approval of dupilumab please visit Drugs[2], or to learn more about the overall development of drug across all indications visit AdisInsight.[3]

 

One thought on “Dupilumab (Dupixant®): Follow up Approval in European Union

Leave a Reply